Patents by Inventor Michael Täger

Michael Täger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseases
    Patent number: 8470855
    Abstract: Compounds of the general formulae (1) and (2) A-B-D-B?-A???(1) and A-B-D-E??(2) in which A and A? may be identical or different and are the residue in which X is S, O, CH2, CH2CH2, CH2O or CH2NH, and Y is H or CN, and * designates a chiral carbon atom preferably in S- or L-configuration; B and B? may be identical or different and are an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkylene residue, cycloalkylene residue, aralkylene residue, heterocycloalkylene residue, heteroarylalkylene residue, arylamidoalkylene residue, heteroarylamidoalkylene residue, unsubstituted or mono- or poly-substituted arylene residue or heteroarylene residue having one or more five-, six- or seven-membered ring(s); D is —S—S— or —Se—Se—; and E is the group —CH2—CH(NH2)—R9 or —CH2—*CH(NH2)—R9 respectively in which R9 is an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkyl residue, cycloalkyl residue, aralkyl residu
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: June 25, 2013
    Assignee: IMTM GmbH
    Inventors: Siegfried Ansorge, Klaus Neubert, Ute Bank, Irene Reichstein, Jürgen Faust, Michael Täger, Petra Fuchs, Bianca Senns
  • Drug preparation comprising ?-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
    Patent number: 7858655
    Abstract: The present invention concerns the use of Provided is a drug composition and a method for using the composition for the prevention and the therapy of neurodegenerative diseases. The combination comprises at least two of the following substances: ?-lipoic acid; ambroxol and one or several inhibitor(s) of the angiotension-converting enzyme (ACE).
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: December 28, 2010
    Assignee: Keyneurotek Pharmaceuticals AG
    Inventors: Peter Röhnert, Frank Striggow, Klaus Reymann, Siegfried Ansorge, Michael Täger, Ulrich Schröder
  • Use of a medicament containing an effector of the glutathione metabolism together with ?-lipoic acid in kidney replacement therapy
    Patent number: 7531567
    Abstract: The invention relates to the use of the combination of n-lipoic acid and effectors of the glutathione metabolism for the treatment of disturbances of the cellular thiol status and accompanying disorders in kidney replacement therapy.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: May 12, 2009
    Assignee: Serumwerk Bernburg AG
    Inventors: Michael Täger, Siegfried Ansorge, Gerhard Fries, Dieter Koegst